ECE2020 ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (142 abstracts)
1Hospital Universitario Central de Asturias, Endocrinologia y Nutricion, Oviedo, Spain; 2Instituto de investigación sanitaria del Principado de Asturias, Endocrinology, Nutrition, Diabetes and Obesity, Oviedo, Spain; 3Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Cancer Epigenetics and Nanomedicine, Oviedo, Spain; 4Centro de Investigación en Nanomateriales y Nanotecnología (CINN), Cancer Epigenetics and Nanomedicine, El Entrego, Spain; 5CIBER – Center for Biomedical Research Network, Rare Diseases, Madrid, Spain; 6Hospital Universitario Central de Asturias, Pediatria, Oviedo, Spain
Introduction and objectives
Type 1 diabetes mellitus (T1DM) is a chronic disease with potential consequences for patients, relatives and ultimately for the healthcare system. The objective of this study is to report the incidence of DM1 in our area as well as assess the characteristics of the patients at the time of diagnosis.
Material and Methods: Retrospective descriptive study. Data was collected through the registration of new diagnoses of T1DM in a third level hospital during 4 years. Medical records at patient’s disease onset were reviewed. In total, data was assessed from 99 patients, including paediatric patients and adults.
Results:
New diagnoses | Total:99 |
• 2015:22 | |
• 2016:26 | |
• 2017:28 | |
• 2018:23 | |
Women/Men | 46/53 |
Age | Mean:28;Median:23 |
• 0–5 y:9% | |
• 6–10 y:16% | |
• 11–15 y:13% | |
• 16–20 y:7% | |
• 21–25 y:9% | |
• 26–30 y:3% | |
• 31–35 y:8% | |
• 36–40 y:5% | |
• 41–45 y:5% | |
• 46–50 y:6% | |
• 51–55 y:6% | |
• 56–60 y:3% | |
• 61–65 y:5% | |
• 66–70 y:4% | |
BMI (only in > 20 years old) | Mean:24.4% |
Symptoms | Diabetic ketoacidosis:17% Cardinal signs:68%;Median of duration:4 weeks. |
Age-Ketoacidosis | • 0–5 y:5;55.5% |
• 6–10 y:5;31% | |
• 11–15 y:3;23% | |
• 16–20 y:2;29% | |
• 36–40 y:1;20% | |
• 61–65 y:1;20% | |
Laboratory analysis | Glycemia(mean):377 mg/dl |
Glycated haemoglobin(mean):10.8% | C-peptide:0.97;Decreased:68.5% |
Previous use of non-insulin antidiabetics | 18 |
Autoantibodies | Included Zinc(n:63): |
• GAD + ,IA2 +,Zn +:25;39.7% | |
• GAD + ,IA2–,Zn +:12;19% | |
• GAD + ,IA2 +,Zn–:7;11.1% | |
• GAD–,IA2 +,Zn +:5;7.9% | |
• GAD + ,IA2–,Zn–:5;7.9% | |
• GAD–,IA2–,Zn +:4;6.3% | |
• GAD–,IA2 +,Zn–:3;4.8% | |
• GAD–,IA2-,Zn–:2;3.2% | No included Zinc(n:36): |
• GAD +,IA2–:16;44.4% | |
• GAD +,IA2 +:13;36.1% | |
• GAD–,IA2–:4;11.1% | |
• GAD–,IA2 +:3;8.3% | |
Autoantibodies-Ketoacidosis | • GAD + ,IA2 + ,Zn + :5;20% |
• GAD + IA2-,Zn + :3;25% | |
• GAD + ,IA2 + ,Zn–:7;43% | |
• GAD-,IA2 +,Zn +:1;20% | |
• GAD +,IA2-,Zn–:2;40% | |
• GAD–,IA2-,Zn +:0 | |
• GAD–,IA2 +,Zn–:0 | |
• GAD–,IA2-,Zn–:0 | |
Haplotypes | n:53 |
• DR3-DR4 + DQ2-DQ8 +:16;30.2% | |
• DR3 + DR4 + DQ2 + DQ8 +:14;26.4% | |
• DR3 + DR4-DQ2 + DQ8–:13;24.5% | |
• DR3-DR4-DQ2-DQ8–:9;17% | |
• DR3 + DR4 + DQ2 + DQ8–:1;1.89% | |
Personal history of autoimmune diseases | No:75 |
Familiar history of DM | T1DM:26 |
T2DM:45 |
Conclusions: T1DM incidence in our area was 7.6/100.000 patients. There were no major changes in the incidence in the different years evaluated. Most newly diagnoses were performed before the age of 25, with a higher incidence between 6 and 10 years old. Less than 20% of patients debuted with ketoacidosis. Children are at greater risk of ketoacidosis at the diagnosis of diabetes. In almost 20% of the T1DM patients, non-insulin antidiabetic drugs were initially used. The most frequently detected autoantibodies were GAD + IA2 + Zn and GAD+IA2-. Greater tendency to ketoacidosis with respect to other combinations in GAD + IA2 + Zn- and GAD + IA2-Zn-. More than 80% of the patients presented positivity in any of haplotypes. The vast majority of the patients did not reported any history of autoimmune diseases. On the other hand, almost a quarter of the patients had family history of T1DM and almost half of T2DM.